Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Healthcare Co., Ltd.

http://www.celltrionhealthcare.com

Latest From Celltrion Healthcare Co., Ltd.

Seventeen And Counting – Bumper Crop Of New EU Filings

Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.

Europe Drug Review

First-Of Kind BMS Drugs Among Myriad New Filings In EU

Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.

Europe Drug Review

Celltrion Allies With 180 Life Sciences On Repurposing Biosimilars

Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.

Deals Biosimilars

Celltrion Wins Brazilian Trastuzumab and Rituximab Tender

Celltrion has won a Brazilian tender to supply two oncology biosimilars – Herzuma (trastuzumab) and Truxima (rituximab) – to the Brazilian market. Based on its successful bid in Brazil, the company plans on expanding its direct sales business model to Peru and Chile in the third quarter of this year.

South America Brazil
See All

Company Information

UsernamePublicRestriction

Register